Filter by: patients
Home > Community Treatment Reports and Side Effects > Clinoril Treatment Report
What is Clinoril?

Clinoril is a brand name for the non steroidal antiinflammatory agent sulindac that is used in the management of inflammatory diseases including osteoarthritis, rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, acute painful shoulder (bursitis/tendonitis)

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Joint pain 3 1 Efficacy_slight
Fibromyalgia 2 0
Other 2 0

See all 3 patients currently taking Clinoril

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Dosages

  400 mg daily 450 mg daily
  2 Number of Patients: 2 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Clinoril (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 2   Did not seem to work: 67%
Side effects too severe 1   Side effects too severe: 33%
Not indicated 1   Not indicated: 33%

See all 3 patients who’ve stopped taking Clinoril

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Clinoril

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Clinoril

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Clinoril

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Clinoril

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Clinoril

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 24, 2012.